TJ Biopharma Co., Ltd.
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Efmedaglutide alfa(Shanmeining) | Phase 3 | GLP-1 receptorProtein / enzyme therapeutic | ObesityType 2 Diabetes |
| Phase 2/3 | CD73Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | IL-6 transProtein / enzyme therapeutic | Inflammatory Bowel Disease Ulcerative Colitis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
August 2028 (1)
Est. primary completion 2028-08-05 · NCT06984588 · CT.gov ↗
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
30 September 2026Topline resultTG103TG103 plus metformin Phase 3 vs dulaglutide (NCT06235086) met its primary endpoint
CSPC Pharmaceutical Group Limited · Source ↗
Financial reports
No financial reports recorded.